Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diasorin SpACHIX:DIAM +0.63%78 3-Year FCF Growth Rate is -8.50% as of Jun. 2026. GuruFocus rates CHIX:DIAM with a GF Score™ of 78/100 and a GF Value™ of €91.12 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 153 Medical Diagnostics & Research companies, Diasorin SpA ranks worse than 77.78% on this metric.
During the past 12 months, Diasorin SpA's average Free Cash Flow per Share Growth Rate was -9.70% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -8.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -3.90% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 7.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Diasorin SpA was 69.40% per year. The lowest was -8.50% per year. And the median was 13.40% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Diasorin SpA 3-Year FCF Growth Rate Related Terms
CHIX:DIAM vs TMO, DHR, NTRA: 3-Year FCF Growth Rate Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA 3-Year FCF Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of -8.50% mean?
Diasorin SpA (CHIX:DIAM) has a 3-Year FCF Growth Rate of -8.50% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Diasorin SpA and its competitors. According to the industry distribution chart, Diasorin SpA ranks #119 out of 153 companies in the Medical Diagnostics & Research industry, placing it in the top 77.8%.
Is Diasorin SpA's 3-Year FCF Growth Rate too high?
Diasorin SpA's current 3-Year FCF Growth Rate is -8.50%. Based on the distribution chart, Diasorin SpA ranks #119 out of 153 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Diasorin SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's 3-Year FCF Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #119 out of 153 companies for 3-Year FCF Growth Rate. This places Diasorin SpA in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 16.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year FCF Growth Rate among Medical Diagnostics & Research companies is 16.10, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year FCF Growth Rate is 16.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current 3-Year FCF Growth Rate is -8.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €91.12, compared to a current price of €74.01 — trading 18.8% below its estimated fair value. The current 3-Year FCF Growth Rate is -8.50%. Diasorin SpA's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current 3-Year FCF Growth Rate is -8.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €74.01 is trading 18.8% below its estimated GF Value™ of €91.12.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for CHIX:DIAM:
3-Year FCF Growth Rate: -8.50%
GF Value™: €91.12 vs. price of €74.01 (18.8% below fair value)
No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score
Get the complete analysis for CHIX:DIAM
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIAM has been successfully added to your 
